An RNA polymerase inhibitor, cyclothiazomycin B1, and its isomer
摘要:
Novel cyclic thiopeptides, cyclothiazomycins B1 (1) and B2 (2), were isolated from Streptomyces sp. A307 as potent hyphal swelling inducing substances. They are stable in the solid state but slowly isomerize with one another in solution. Degradation experiments and spectroscopic analyses disclosed that they comprise unique tricyclic structures each containing a dehydroalanine, and two dehydrohomoalanine residues, along with three thiazolines, three thiazoles, and a trisubstituted pyridine. Cyclothiazomycin B1 (1) is expected to be a powerful tool for DNA-RNA transcription studies, because this cyclopeptide inhibits DNA-dependent RNA synthesis by bacteriophage RNA polymerases. (c) 2006 Elsevier Ltd. All rights reserved.
The first reported synthesis of saramycetic acid, a degradation product of the complex thiopeptide antibiotic cyclothiazomycin, is achieved in nine steps and 11% overall yield from diethoxyacetonitrile by a strategy, which incorporates two Hantzsch thiazole syntheses using thioamides prepared from the corresponding nitriles without the use of gaseous H2S. The synthetic material was transformed to methyl saramycetate, which had spectroscopic Properties in excellent agreement with the literature data. (c) 2007 Elsevier Ltd. All rights reserved.
Structure of cyclothiazomycin, a unique polythiazole-containing peptide with renin inhibitory activity. Part 1. Chemistry and partial structures of cyclothiazomycin
Cyclothiazomycin is a novel renin inhibitor produced by .NR0516 (IC50 1.66μM). Its molecular formula was determined to be C59H64H18O14S7 (MW .1472) based on high-resolution FAB mass and NMR spectroscopy. Five fragments of cyclothiazomycin containing thiazole, thiazoline, heterocyclic chromophore were clarified by extensive 2D-NMR experiments.
Cyclothiazomycin是通过产生一个新的肾素抑制剂.NR0516(IC 50 1.66μM)。根据高分辨率FAB质谱和NMR光谱确定其分子式为C 59 H 64 H 18 O 14 S 7(MW .1472)。通过广泛的2D-NMR实验澄清了含有噻唑,噻唑啉,杂环发色团的环噻唑霉素的五个片段。
Highly Efficient Borylation Suzuki Coupling Process for 4-Bromo-2-ketothiazoles: Straightforward Access to Micrococcinate and Saramycetate Esters
The first palladium-catalyzed borylation of 4-bromo-2-ketothiazoles followed by a Suzuki cross-coupling reaction with haloheteroaromatics using Buchwaid's Cy-JohnPhos and XPhos ligands is reported. The methodology has allowed the fast preparation of highly valuable 4-pyridinyl- and 4-thiazolyl-2-ketothiazoles as common subunits of thiopeptide antibiotics. As direct applications, novel concise syntheses of a sulfomycinamate thio-analogue as well as micrococcinate and saramycetate esters are described.
Synthesis of saramycetic acid
作者:Christian Glover、Eleanor A. Merritt、Mark C. Bagley
DOI:10.1016/j.tetlet.2007.07.111
日期:2007.9
The first reported synthesis of saramycetic acid, a degradation product of the complex thiopeptide antibiotic cyclothiazomycin, is achieved in nine steps and 11% overall yield from diethoxyacetonitrile by a strategy, which incorporates two Hantzsch thiazole syntheses using thioamides prepared from the corresponding nitriles without the use of gaseous H2S. The synthetic material was transformed to methyl saramycetate, which had spectroscopic Properties in excellent agreement with the literature data. (c) 2007 Elsevier Ltd. All rights reserved.
An RNA polymerase inhibitor, cyclothiazomycin B1, and its isomer
Novel cyclic thiopeptides, cyclothiazomycins B1 (1) and B2 (2), were isolated from Streptomyces sp. A307 as potent hyphal swelling inducing substances. They are stable in the solid state but slowly isomerize with one another in solution. Degradation experiments and spectroscopic analyses disclosed that they comprise unique tricyclic structures each containing a dehydroalanine, and two dehydrohomoalanine residues, along with three thiazolines, three thiazoles, and a trisubstituted pyridine. Cyclothiazomycin B1 (1) is expected to be a powerful tool for DNA-RNA transcription studies, because this cyclopeptide inhibits DNA-dependent RNA synthesis by bacteriophage RNA polymerases. (c) 2006 Elsevier Ltd. All rights reserved.